Certain HIV treatment less effective when used with anti-TB therapy

August 04, 2008

Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy, according to a study in the August 6 issue of JAMA, a theme issue on HIV/AIDS.

Andrew Boulle, M.B.Ch.B., M.Sc., of the University of Cape Town, South Africa, presented the findings of the study at a JAMA media briefing on HIV/AIDS.

Combination antiretroviral therapy (ART) is frequently initiated in resource-limited countries when patients are being treated for tuberculosis. Co-administration of ART and anti-tubercular therapy may be complicated by shared toxicity or adverse drug interactions, according to background information in the article. Rifampicin-based anti-tubercular therapy reduces the plasma concentrations of the antiretroviral agents efavirenz and nevirapine. The virological consequences of these interactions are not well known.

Dr. Boulle and colleagues conducted a study to assess the effectiveness of efavirenz- or nevirapine-based combination ART used with rifampicin-based anti-tubercular therapy. The researchers analyzed clinical data collected from a community-based South African antiretroviral treatment program, in which adults were enrolled between May 2001 and June 2006 and were followed up until the end of 2006. The analysis included 2,035 individuals who started antiretroviral therapy with efavirenz (1,074 with tuberculosis) and 1,935 with nevirapine (209 with tuberculosis).

The researchers found that patients with tuberculosis initiating nevirapine were about twice as likely to have elevated viral loads during follow-up than those without tuberculosis (at six months, 16.3 percent vs. 8.3 percent). In the time-to-event analysis of confirmed virological failure, patients starting nevirapine with tuberculosis treatment were more than twice as likely to develop virological failure sooner. In spite of these differences, 80 percent of patients in the initial nevirapine-rifampicin group were virologically suppressed at 18 months duration of ART. There were no differences between patients starting efavirenz with and without tuberculosis treatment, or in patients developing tuberculosis while on nevirapine or efavirenz compared to those free of tuberculosis on the same antiretroviral drug.

The authors speculate that these differences, present in patients who start nevirapine-based antiretrovirals with tuberculosis, but not in those who develop tuberculosis once already established on nevirapine-based antiretroviral therapy "- could be the result of the limited power of the latter analysis to detect a difference- An alternative explanation, however, is a drug interaction mediated by rifampicin during the lead-in dosing phase of nevirapine."

"Given the continued reliance on nevirapine-containing ART regimens in Africa, together with the important role tuberculosis services play as an entry point for ART, further prospective studies exploring this outcome are warranted. One of the most striking aspects of our study was the demonstration that 40 percent of patients starting ART in recent years have concurrent tuberculosis, underscoring the public health importance of improving affordable treatment options for patients infected with HIV and tuberculosis in this setting."

JAMA and Archives Journals

---

---

	The White Plague: Tuberculosis, Man and Society by Jean Dubos (Author)
	Tuberculosis and Nontuberculous Mycobacterial Infections by David Schlossberg (Editor) Here's an up-to-date 4th Edition of the resource that discusses tuberculosis at a time when major outbreaks and drug-resistant strains of the disease are making headlines.
	The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost by Frank Ryan (Author) Ryan, a physician, offers a history of the cure for tuberculosis, including accounts of the people and scientists involved. The final chapter spells out a renewed threat in the congruence of AIDS and tuberculosis.
	Invincible Microbe: Tuberculosis and the Never-Ending Search for a Cure by Jim Murphy (Author), Alison Blank (Author) This is the story of a killer that has been striking people down for thousands of years: tuberculosis. After centuries of ineffective treatments, the microorganism that causes TB was identified, and the cure was thought to be within reach—but drug-resistant varieties continue to plague and panic the human race. The “biography” of this deadly germ, an account of the diagnosis, treatment, and “cure” of the disease over time, and the social history of an illness that could strike anywhere but was most prevalent among the poor are woven together in an engrossing, carefully researched narrative. Bibliography, source notes, index.
	Tuberculosis: A Comprehensive Clinical Reference, 1e by H. Simon Schaaf MBChB(Stellenbosch) MMed Paed(Stellenbosch) DCM(Stellenbosch) MD Paed(Stellenbosch) (Editor), Alimuddin Zumla BSc.MBChB.MSc.PhD.FRCP(Lond).FRCP(Edin).FRCPath(UK) (Editor) This book provides all the vital information you need to know about tuberculosis, especially in the face of drug-resistant strains of the disease. Coverage includes which patient populations face an elevated risk of infection, as well as which therapies are appropriate and how to correctly monitor ongoing treatment so that patients are cured. Properly administer screening tests, interpret their results, and identify manifestations of the disease, with authoritative guidance from expert clinicians from around the world.Discusses screening tests for tuberculosis so you can interpret their results and identify not only common manifestations of the disease, but also those that are comparatively rare-such as tuberculosis in pregnant women. Covers all clinical aspects of tuberculosis in...
	A Child of Sanitariums: A Memoir of Tuberculosis Survival and Lifelong Disability by Gloria Paris (Author) This dramatic memoir recounts one woman's experience with skeletal tuberculosis, which she contracted at the age of five in the 1930s. It recounts her next nine years living in tuberculosis sanatoriums where she underwent many treatments for the disease and was finally released when she was 14. Despite her subsequent disablement, she went on to marry and have three children, work as a micro-biologist, perform as a comedienne, and serve as an advocate for minority groups. By turns deeply affecting and hilarious, this memoir provides a glimpse into a still-dangerous disease and is a testament to the power of human perseverance and hope.
	Captain of Death: The Story of Tuberculosis by Thomas M. Daniel (Author) The dramatic story of tuberculosis is told here in a straightforward and accessible style. It presents the stories of persons connected with the disease, either as victims, or as those who made contributions to our knowledge of it; in addition to these personal accounts, the book unfolds the history and explains the pathogenesis of TB. The re-emergence of tuberculosis as a major American public health hazard has focused much attention on this ancient disease. This book offers a comprehensive account of the disease from prehistoric times through to the present day, detailing the attempts to eradicate it completely. Its four separate sections (the spread of tuberculosis; its infectious nature; susceptibility to it; and methods of treatment) are linked through the device of presenting...
	The Return of the White Plague: Global Poverty and the "New" Tuberculosis by Matthew Gandy (Editor), Alimuddin Zumla (Editor) A global health catastrophe threatens to undermine all efforts to eradicate poverty and human suffering.The dramatic increase since the 1980s in the global prevalence of tuberculosis, a disease destined as recently as thirty years ago for complete eradication, is a story of medical failure. A pandemic whose geography defies simple categorization, it ranges from schools in the UK to prisons in Russia, from refugee camps in central Africa to affluent suburbs in North America. The 'new' tuberculosis is derived from a combination of different developments such as collapsing health-care services, shifting patterns of poverty and inequality, the spread of HIV, and the emergence of virulent drug-resistant strains. This collection provides an international survey of current thought on the spread...
	Tuberculosis TUBERCULOSIS Last updated 2/25/2012 Table of Contents - Background, Statistics, Epidemiology - Method of Spread - Pathophysiology - History - Risk factors - Differential Diagnosis - Physical Exam - Workup - Treatment - More to come
	The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease by CHARLOTTE ROBERTS (Author), JANE BUIKSTRA (Author) Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders.